Straits Times Index
3,276.32 -11.43 (-0.35%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,106.64 +27.78 (+0.34%) Bitcoin USD
64,395.96 +541.66 (+0.85%) CMC Crypto 200
1,389.78 -6.76 (-0.48%)
REGN Jun 2024 540.000 call
| Previous close | 260.00 |
| Open | 260.00 |
| Bid | 316.00 |
| Ask | 325.00 |
| Strike | 540.00 |
| Expiry date | 2024-06-21 |
| Day's range | 260.00 - 260.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksEXEL vs. REGN: Which Stock Is the Better Value Option?
EXEL vs. REGN: Which Stock Is the Better Value Option?
ZacksRegeneron (REGN) Reports Next Week: What You Should Expect
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
